465 related articles for article (PubMed ID: 27890396)
1. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
[TBL] [Abstract][Full Text] [Related]
2. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ
Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945
[TBL] [Abstract][Full Text] [Related]
4. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
[TBL] [Abstract][Full Text] [Related]
5. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci.
Dale JB; Penfound TA; Chiang EY; Walton WJ
Vaccine; 2011 Oct; 29(46):8175-8. PubMed ID: 21920403
[TBL] [Abstract][Full Text] [Related]
6. Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptides.
Aranha MP; Penfound TA; Spencer JA; Agarwal R; Baudry J; Dale JB; Smith JC
J Biol Chem; 2020 Mar; 295(12):3826-3836. PubMed ID: 32029479
[TBL] [Abstract][Full Text] [Related]
7. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
Smeesters PR; Dramaix M; Van Melderen L
Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033
[No Abstract] [Full Text] [Related]
8. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
[TBL] [Abstract][Full Text] [Related]
9. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a 26-valent group A streptococcal vaccine.
Hu MC; Walls MA; Stroop SD; Reddish MA; Beall B; Dale JB
Infect Immun; 2002 Apr; 70(4):2171-7. PubMed ID: 11895984
[TBL] [Abstract][Full Text] [Related]
11. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
Wozniak A; Scioscia N; García PC; Dale JB; Paillavil BA; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM
Microbiol Immunol; 2018 Jun; 62(6):395-404. PubMed ID: 29704396
[TBL] [Abstract][Full Text] [Related]
12. Immune Cross-Opsonization Within emm Clusters Following Group A Streptococcus Skin Infection: Broadening the Scope of Type-Specific Immunity.
Frost HR; Laho D; Sanderson-Smith ML; Licciardi P; Donath S; Curtis N; Kado J; Dale JB; Steer AC; Smeesters PR
Clin Infect Dis; 2017 Oct; 65(9):1523-1531. PubMed ID: 29020160
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of synthetic, M type-specific peptides as antigens in a multivalent group A streptococcal vaccine.
Bruner M; James A; Beall B; Carlone GM; Ades E; Johnson S; Guarner J; Sampson J
Vaccine; 2003 Jun; 21(21-22):2698-703. PubMed ID: 12798606
[TBL] [Abstract][Full Text] [Related]
14. Design of Broadly Cross-Reactive M Protein-Based Group A Streptococcal Vaccines.
Aranha MP; Penfound TA; Salehi S; Botteaux A; Smeesters P; Dale JB; Smith JC
J Immunol; 2021 Aug; 207(4):1138-1149. PubMed ID: 34341168
[TBL] [Abstract][Full Text] [Related]
15. Recombinant tetravalent group A streptococcal M protein vaccine.
Dale JB; Chiang EY; Lederer JW
J Immunol; 1993 Aug; 151(4):2188-94. PubMed ID: 8345202
[TBL] [Abstract][Full Text] [Related]
16. Group A streptococcus expresses a trio of surface proteins containing protective epitopes.
Niedermeyer SE; Penfound TA; Hohn C; Li Y; Homayouni R; Zhao J; Dale JB
Clin Vaccine Immunol; 2014 Oct; 21(10):1421-5. PubMed ID: 25080552
[TBL] [Abstract][Full Text] [Related]
17. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
[TBL] [Abstract][Full Text] [Related]
18. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
[TBL] [Abstract][Full Text] [Related]
19. FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model.
Ma C; Liu Z; Li W; Qian X; Zhang S; Gao X; Jiang S; Wei L
Microbes Infect; 2014 May; 16(5):409-18. PubMed ID: 24704476
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
